Systolic Blood Pressure Variability Linked to Mortality, Morbidity

Share this content:
Systolic Blood Pressure Variability Linked to Mortality, Morbidity
Systolic Blood Pressure Variability Linked to Mortality, Morbidity

THURSDAY, Sept. 29, 2016 (HealthDay News) -- Systolic blood pressure variability (SBPV) is associated with mortality, coronary heart disease (CHD), stroke, and end-stage renal disease (ESRD), according to a study published in the Sept. 27 issue of the Journal of the American College of Cardiology.

Elvira O. Gosmanova, M.D., from the Stratton Veterans Affairs Medical Center in Albany, N.Y., and colleagues examined the impact of increased visit-to-visit variability in a large cohort of U.S. veterans. Data were included for 2,865,157 patients with eight or more outpatient BP measurements. SBPV was measured and correlated with all-cause mortality, incident CHD, stroke, and ESRD.

The researchers found that higher intraindividual SBPV was seen in association with sociodemographic variables (older age, male sex, African-American race, divorced or widowed status), clinical characteristics (lower baseline estimated glomerular filtration rate, higher SBP, and diastolic BP), and comorbidities (presence of diabetes, hypertension, cardiovascular disease, and lung disease). For standard deviation quartile 2 through 4 versus the first quartile, the multivariable-adjusted hazard ratios associated with all-cause mortality, CHD, stroke, and ESRD were incrementally higher.

"Higher SBPV in individuals with and without hypertension was associated with increased risks of all-cause mortality, CHD, stroke, and ESRD," the authors write. "Further studies are needed to determine interventions that can lower SBPV and their impact on adverse health outcomes."

Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Belimumab Aids Anti-dsDNA, Hypocomplementemic Lupus

Belimumab Aids Anti-dsDNA+, Hypocomplementemic Lupus

More SLE Responder Index responders at week 52 in the belimumab group versus the placebo group

Too Few Adults Taking Epilepsy Meds Have Seizure Control

Too Few Adults Taking Epilepsy Meds Have Seizure ...

Ninety percent of those with active epilepsy take meds; 44 percent of those report seizure control

Pediatric Exposures to Liquid Nicotine Down From 2015 to 2016

Pediatric Exposures to Liquid Nicotine Down From 2015 ...

Still poses serious risk to children; decrease likely in part to law requiring child-resistant packaging

is free, fast, and customized just for you!

Already a member?

Sign In Now »